Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
Question
Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
Direct answer
Biohaven monetizes pipeline IP through $795 million in milestone and licensing potential, reducing near-term dilutive equity financing needs. — bullish pressure on BHVN via non-dilutive milestone cash inflow from $795M licensing partnership.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-28
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Biohaven partners with SK Biopharmaceuticals in $795M licensing deal”, revision 1, evidence through 2026-08-28. https://marketontology.com/catalysts/2026-08-28/biohaven-partners-with-sk-biopharmaceuticals-in-795m-licensing-deal-bfac40
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| BHVN | ▲Bull | 1–5 days | non-dilutive milestone cash inflow from $795M licensing partnership | 55 |
Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
Biohaven monetizes pipeline IP through $795 million in milestone and licensing potential, reducing near-term dilutive equity financing needs. — bullish pressure on BHVN via non-dilutive milestone cash inflow from $795M licensing partnership.
Source reports Biohaven licensing deal with SK Biopharmaceuticals worth up to $795 million for opakalim.
- SourceSource reports Biohaven licensing deal with SK Biopharmaceuticals worth up to $795 million for opakalim.
- TransmissionBiohaven monetizes pipeline IP through $795 million in milestone and licensing potential, reducing near-term dilutive equity financing needs.
- SummaryBiohaven entered a $795 million global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel program. The deal focuses on opakalim for focal epilepsy treatment. The non-dilutive capital milestone structure provides balance sheet support for pipeline development.
- BHVNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- BHVN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- BHVN price vs. pre-event level
- BHVN volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Why Biohaven Stock Was Rocking the Market This Week · Polygon · 2026-08-28
Related catalysts
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimBHVN
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimBHVN
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimBHVN
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.